Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of apremilast in pediatric moderate to severe plaque psoriasis
2015-003314-24Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Celgene Corporation. Primary endpoints: Safety and tolerability of apremilast and Pharmacokinetics of apremilast. Started Nov 2015; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-003314-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003314-24.